Christopher Mann | Scientific And Regulatory Affairs Director
Asphalion, S.L.

Christopher Mann, Scientific And Regulatory Affairs Director, Asphalion, S.L.

Christopher has a PhD in Biochemistry (Molecular biology) in gene therapy for muscular dystrophy. He has been an academic researcher in gene therapy, muscle regeneration and muscular dystrophy as well as diabetes for 15 year and has published numerous original research papers and review articles in peer reviewed journals. He is also an expert in medical and scientific writing for Advanced Therapy Medicinal Products (ATMPs), Biosimilars, Biological, Biotechnological and other Innovative products, and has also additional expertise in pediatric development (EU and FDA), Scientific Advice/ Pre-IND meetings and Centralized Procedures. He has also been work package leader for several research consortia, including projects with ATMPs.

Appearances:



Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 16:00

Perspectives on the ATMP Regulatory landscape: approaches to harmonisation and identifying early translational issues

  • Introduction to the Accelerating Research & Development for Advanced Therapies (ARDAT) project
  • Regulatory issues encountered during early stage ATMP development in small biotechs and SMEs
  • Future scope and tools for regulatory harmonisation and improving ATMP development
Christopher Mann, Scientific And Regulatory Affairs Director, Asphalion, S.L.
last published: 10/May/21 08:45 GMT

back to speakers